Skip to content

Anidulafungin

Echinocandin Antifungal — ANTIINFECTIVES FOR SYSTEMIC USE

Also known as: ecalta, eraxis, LY 303366, LY-303366

OfpEMA approvedFDA approvedATC J02AX06

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Anidulafungin is an ofp drug in the Echinocandin Antifungal class catalogued in DrugCentral. It was first approved by the FDA in 2006. DrugCentral lists 1 molecular target, including GSC1. Recorded indications include Candida Peritonitis, Candidemia, Candidiasis of the esophagus and Disseminated candidiasis.

  • Approval status: ofp (first approved 2006 by the FDA).
  • Drug class: Echinocandin Antifungal.
  • Molecular targets: GSC1 (1 listed in DrugCentral).
  • Indications: Candida Peritonitis, Candidemia, Candidiasis of the esophagus, Disseminated candidiasis and Intra-Abdominal Candida Abscess.
  • ATC code: J02AX06 (Other antimycotics for systemic use).
  • Molecular formula: C58H73N7O17; molecular weight 1140.25 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (5)

  • Candida Peritonitis
  • Candidemia
  • Candidiasis of the esophagus
  • Disseminated candidiasis
  • Intra-Abdominal Candida Abscess

Off-label uses (1)

  • Oropharyngeal Candidiasis

Contraindications (2)

  • Disease of liver
  • Liver function tests abnormal

Mechanism & targets

Established pharmacologic classEchinocandin Antifungal

Molecular targets (1)

TargetGeneActionActivity
Beta-1,3-glucan synthase catalytic subunit 1GSC1inhibitorIC50 7.75

Regulatory approvals (2)

DateAgencyMarketed asApplicantOrphan
2007-09-20EMA——
2006-02-17FDA—VICURON

ATC classification

ATC codeTherapeutic hierarchy
J02AX06ANTIINFECTIVES FOR SYSTEMIC USE › ANTIMYCOTICS FOR SYSTEMIC USE › ANTIMYCOTICS FOR SYSTEMIC USE › Other antimycotics for systemic use

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Multiple organ dysfunction syndrome330.5
Septic shock212.5
Drug ineffective172.7
Candida infection161.7
Sepsis133.0
Enterococcal infection116.5
Protothecosis114.6
Pathogen resistance108.1
Systemic candida106.8
Drug resistance96.1
Haemodynamic instability94.5
Fungaemia94.1

Chemical structure

Molecular formulaC58H73N7O17
Molecular weight1140.25 g/mol
CAS number166663-25-8
InChIKeyJHVAMHSQVVQIOT-FUVWCVBOSA-N
PubChem CID166548
CCCCCOC1=CC=C(C=C1)C1=CC=C(C=C1)C1=CC=C(C=C1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)C(NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)C(NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@@H](C)O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Anidulafungin used for?

DrugCentral lists the following indications for Anidulafungin: Candida Peritonitis, Candidemia, Candidiasis of the esophagus, Disseminated candidiasis and Intra-Abdominal Candida Abscess.

How does Anidulafungin work?

Its molecular targets in DrugCentral include GSC1 (inhibitor).

When was Anidulafungin first approved?

Anidulafungin was first approved by the FDA in 2006.

What drug class does Anidulafungin belong to?

Anidulafungin is in the Echinocandin Antifungal class.

What is the chemical formula of Anidulafungin?

Anidulafungin has the molecular formula C58H73N7O17 and a molecular weight of 1140.25 g/mol.

Browse: all drugs starting with A · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFP
First approval2006-02-17
AgencyFDA
Targets1
Indications5
FormulaC58H73N7O17
DrugCentral ID4357
Interactive profile